By: John Schieszer
Increasing the visibility and representation of sexual and gender minorities (SGM) in clinical trials is vital for developing evidence-based and tailored care that can eliminate cancer disparities, according to B.R. Simon Rosser, PhD, professor and director of sexual health research at the University of Minnesota in Minneapolis.










